Etoposide kinetics in patients with obstructive jaundice

Area of Science:

• Pharmacology
• Clinical Pharmacology
• Oncology

Background:

• Obstructive jaundice can alter drug metabolism and excretion.
• Etoposide is a chemotherapy agent commonly used in cancer treatment.
• Understanding etoposide's behavior in patients with jaundice is crucial for safe and effective therapy.

Purpose of the Study:

• To investigate the pharmacokinetics of etoposide in patients with obstructive jaundice.
• To determine the urinary excretion patterns of etoposide and etoposide glucuronide in this patient group.
• To assess the need for etoposide dose adjustments in patients with obstructive jaundice and normal renal function.

Main Methods:

• Kinetics and urinary excretion of etoposide and etoposide glucuronide were measured.
• 11 patients with obstructive jaundice and 23 healthy controls were included.
• Etoposide pharmacokinetics were also assessed during hyperbilirubinemia and after resolution.

Main Results:

• Mean etoposide clearance, half-life, and volume of distribution were not significantly different between jaundiced patients and controls.
• Urinary excretion of etoposide was higher in jaundiced patients (46%) compared to controls (35%).
• Urinary excretion of etoposide glucuronide was lower in jaundiced patients (15%) compared to controls (29%).
• Biliary excretion of etoposide was negligible.
• Total etoposide clearance remained similar, with renal excretion compensating for potentially decreased hepatic metabolism.

Conclusions:

• Etoposide pharmacokinetics are not significantly altered by obstructive jaundice in patients with normal renal function.
• Increased renal excretion of etoposide appears to compensate for potential decreases in hepatic metabolism.
• No etoposide dose reduction is necessary for patients with obstructive jaundice and normal renal function.